Quartz8d agobearish
Merck cuts 2026 profit forecast on Terns acquisition chargesThe pharma giant now expects adjusted earnings of $2.66 to $2.76 per share, down from a prior range of $5.04 to $5.16
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
323last 24h
2137last 7d
379● bullish (7d)
187● bearish (7d)
204publishers
The Wall Street Journal8d agobearish
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom LineMerck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.